NashBio COO Elizabeth Ann Stringer is a guest speaker at Health2Tech on September 15th.

At NashBio, we make complex healthcare data easy to use. From idea to execution, we leverage real-world clinical, genomic and imaging data to advance the discovery and development of new therapeutics and diagnostics. A for-profit subsidiary of Vanderbilt University Medical Center, NashBio was launched in 2018 with a mission to harness extensive real-world genomics and other multi-modal datasets, along with powerful bioinformatics tools, to build and deliver a wide range of data products and services that support life science R&D. Our company works with clients in pharma, biotech, diagnostics, medical devices and other life sciences domains to support their most critical R&D use cases. We believe smarter data ultimately enables better outcomes for our clients. Leveraging Vanderbilt University Innovation, NashBio’s hallmarks are deep, high quality, longitudinal datasets that are demographically diverse and clinically relevant, integrated and curated for ease of customer use. In 2023, NashBio launched the Alliance for Genomic Discovery (AGD), in collaboration with Illumina and eight leading pharmaceutical companies, to build one the world’s largest collections of whole genome sequence data linked to de-identified medical records for drug discovery & development. For more information about NashBio, please visit our website.